MedTrace Logo

Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways

NCT02525887 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2016-05-06

No results posted yet for this study

Summary

This observation will look at patient care decisions of the primary healthcare provider utilizing the results of the DNA testing of patients' metabolic pathways using 2C19, 2C9, 2D6, 3A4, Factor II, Factor V and MTHFR and VKORC1. Findings of the data collection will be published to optimize the benefits of pharmacogenomics testing and publish health outcomes.

Conditions

Interventions

OTHER

Observation

Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.

Sponsors & Collaborators

  • IFG Medical

    collaborator INDUSTRY

  • Bracane Company

    lead INDUSTRY

Principal Investigators

  • Kirk Allan · IFG Medical

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02525887 on ClinicalTrials.gov